VEGF Cancer Research Results

VEGF, Vascular endothelial growth factor: Click to Expand ⟱
Source: HalifaxProj (inhibit)
Type:
A signal protein produced by many cells that stimulates the formation of blood vessels. Vascular endothelial growth factor (VEGF) is a signal protein that plays a crucial role in angiogenesis, the process by which new blood vessels form from existing ones. This process is vital for normal physiological functions, such as wound healing and the menstrual cycle, but it is also a key factor in the growth and spread of tumors in cancer.
Because of its significant role in tumor growth and progression, VEGF has become a target for cancer therapies. Anti-VEGF therapies, such as monoclonal antibodies (e.g., bevacizumab) and small molecule inhibitors, aim to inhibit the action of VEGF, thereby reducing blood supply to tumors and limiting their growth. These therapies have been used in various types of cancer, including colorectal, lung, and breast cancer.
CRC, Colorectal Cancer: Click to Expand ⟱
Colorectal cancer is a broader term that encompasses both colon and rectal cancer.
Scientific Papers found: Click to Expand⟱
6518- BCP,    beta-Caryophyllene Induces Apoptosis and Inhibits Angiogenesis in Colorectal Cancer Models
- vitro+vivo, CRC, HCT116
angioG↓, VEGF↓, TumVol↓, HSP60/HSPD1↓, HTRA↓, survivin↓, XIAP↓, P21↑, TumCP↓, TumCMig↓, TumCG↓, Dose↝,
6496- BCP,    β-Caryophyllene Induces Apoptosis and Inhibits Angiogenesis in Colorectal Cancer Models
- vitro+vivo, CRC, HCT116 - in-vitro, Nor, HUVECs
angioG↓, VEGF↓, TumVol↓, Apoptosis↑, HSP60/HSPD1↓, HTRA↓, survivin↓, XIAP↓, P21↑, *toxicity↓, *neuroP↑, *ROS↓, *COX2↓, *Inflam↓, *cardioP↑, AntiCan↑, ChemoSen↑, ROS↑, MMP↑, Bax:Bcl2↑, TumCG↓,
2745- BetA,    Betulinic acid inhibits colon cancer cell and tumor growth and induces proteasome-dependent and -independent downregulation of specificity proteins (Sp) transcription factors
- in-vitro, CRC, RKO - in-vitro, CRC, SW480 - in-vivo, NA, NA
Apoptosis↑, TumCG↓, Sp1/3/4↓, survivin↓, VEGF↓, p65↓, EGFR↓, cycD1/CCND1↓, ROS↑, MMP↓,
1169- Bos,    Boswellic Acid Inhibits Growth and Metastasis of Human Colorectal Cancer in Orthotopic Mouse Model By Downregulating Inflammatory, Proliferative, Invasive, and Angiogenic Biomarkers
- in-vivo, CRC, NA
TumCG↓, TumVol↓, Weight∅, ascitic↓, TumMeta↓, Ki-67↓, CD31↓, NF-kB↓, COX2↓, Bcl-2↓, Bcl-xL↓, IAP1↓, survivin↓, cycD1/CCND1↓, ICAM-1↓, MMP9↓, CXCR4↓, VEGF↓,
1422- Bos,    Boswellic acid exerts antitumor effects in colorectal cancer cells by modulating expression of the let-7 and miR-200 microRNA family
- in-vitro, CRC, NA - in-vivo, NA, NA
5LO↓, TumCG↓, Let-7↑, miR-200b↑, NF-kB↓, cMyc↓, cycD1/CCND1↓, MMP9↓, CXCR4↓, VEGF↓, Bcl-xL↓, survivin↓, IAP1↓, XIAP↓, TumCG↓, CDK6↓, Vim↓, E-cadherin↑,
6179- Cro,    Crocetin suppresses the growth and migration in HCT-116 human colorectal cancer cells by activating the p-38 MAPK signaling pathway
- NA, CRC, HCT116
TumCMig↓, VEGF↓, MMP9↓, p‑p38↑, TumCP↓,
6303- Cro,    Crocetin treatment inhibits proliferation of colon cancer cells through down-regulation of genes involved in the inflammation
- in-vitro, CRC, HCT116 - in-vitro, CRC, DU145
NF-kB↓, VEGF↓, MMP9↓, Inflam↓, HMGB1↓, IL6↓, IL8↓, TumCG↓, Apoptosis↑,
811- GAR,    Garcinol exhibits anti-proliferative activities by targeting microsomal prostaglandin E synthase-1 in human colon cancer cells
- in-vitro, CRC, HT-29
mPGES-1↓, Hif1a↓, VEGF↓, CXCR4↓, MMP2↓, MMP9↓, Casp3↑, TumCP↓, PGE2↓,
1116- GI,    6-Shogaol Inhibits the Cell Migration of Colon Cancer by Suppressing the EMT Process Through the IKKβ/NF-κB/Snail Pathway
- in-vitro, Colon, Caco-2 - in-vitro, CRC, HCT116
TumCG↓, Apoptosis↑, TumCMig↓, MMP2↓, N-cadherin↓, IKKα↓, p‑NF-kB↓, Snail↓, VEGF↓,
7469- Hops,    CHEMOPREVENTIVE PROPERTIES OF SPENT HOPS (HUMULUS LUPULUS L.) EXTRACT AGAINST ANGIOGENESIS, INVASION AND MIGRATION OF COLORECTAL CANCER CELLS
- in-vitro, CRC, SW48 - in-vitro, CRC, HT29
angioG↓, TumCI↓, TumCMig↓, MMP2↓, MMP9↓, VEGF↓, Hif1a↓, chemoPv↑,
6493- Nimb,    Nimbolide, a Limonoid Triterpene, Inhibits Growth of Human Colorectal Cancer Xenografts by Suppressing the Proinflammatory Microenvironment
- in-vivo, CRC, HCT116 - vitro+vivo, CRC, HT29
TumCP↓, Apoptosis↑, NF-kB↓, IKKα↓, Bcl-2↓, Bcl-xL↓, survivin↓, Mcl-1↓, cMyc↓, cycD1/CCND1↓, MMP9↓, CXCR4↓, ICAM-1↓, VEGF↓, angioG↓, TumCG↓,
963- SFN,    Sulforaphane inhibits hypoxia-induced HIF-1α and VEGF expression and migration of human colon cancer cells
- in-vitro, CRC, HCT116 - in-vitro, GC, AGS
Hif1a↓, VEGF↓, angioG↓, Akt∅, ERK∅,
5222- TQ,    Thymoquinone chemosensitizes colon cancer cells through inhibition of NF-κB
- in-vitro, CRC, COLO205 - in-vitro, CRC, HCT116
tumCV↓, ChemoSen↑, p‑p65↓, NF-kB↓, VEGF↓, cMyc↓, Bcl-2↓, ROS↑,
3397- TQ,    Thymoquinone: A Promising Therapeutic Agent for the Treatment of Colorectal Cancer
- Review, CRC, NA
ChemoSen↑, *Half-Life↝, *BioAv↝, *antiOx↑, *Inflam↓, *hepatoP↑, TumCP↓, TumCCA↑, Apoptosis↑, angioG↑, selectivity↑, JNK↑, p38↑, p‑NF-kB↑, ERK↓, PI3K↓, PTEN↑, Akt↓, mTOR↓, EMT↓, Twist↓, E-cadherin↓, ROS⇅, *Catalase↑, *SOD↑, *GSTA1↑, *GPx↑, *PGE2↓, *IL1β↓, *COX2↓, *MMP13↓, MMPs↓, TumMeta↓, VEGF↓, STAT3↓, BAX↑, Bcl-2↑, Casp9↑, Casp7↑, Casp3↑, cl‑PARP↑, survivin↓, cMyc↓, cycD1/CCND1↓, p27/CDKN1B↑, P21↑, GSK‐3β↓, β-catenin/ZEB1↓, chemoP↑,

Showing Research Papers: 1 to 14 of 14

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 14

Pathway results for Effect on Cancer / Diseased Cells:


NA, unassigned(tgid=0) ⓘ

HSP60/HSPD1↓, 2,   HTRA↓, 2,  

Redox & Oxidative Stress(tgid=1) ⓘ

ROS↑, 3,   ROS⇅, 1,  

Mitochondria & Bioenergetics(tgid=3) ⓘ

MMP↓, 1,   MMP↑, 1,   XIAP↓, 3,  

Core Metabolism/Glycolysis(tgid=4) ⓘ

cMyc↓, 4,  

Cell Death(tgid=5) ⓘ

Akt↓, 1,   Akt∅, 1,   Apoptosis↑, 6,   BAX↑, 1,   Bax:Bcl2↑, 1,   Bcl-2↓, 3,   Bcl-2↑, 1,   Bcl-xL↓, 3,   Casp3↑, 2,   Casp7↑, 1,   Casp9↑, 1,   IAP1↓, 2,   JNK↑, 1,   Mcl-1↓, 1,   p27/CDKN1B↑, 1,   p38↑, 1,   p‑p38↑, 1,   survivin↓, 7,  

Kinase & Signal Transduction(tgid=6) ⓘ

Sp1/3/4↓, 1,  

Transcription & Epigenetics(tgid=7) ⓘ

tumCV↓, 1,  

DNA Damage & Repair(tgid=10) ⓘ

cl‑PARP↑, 1,  

Cell Cycle & Senescence(tgid=11) ⓘ

cycD1/CCND1↓, 5,   P21↑, 3,   TumCCA↑, 1,  

Proliferation, Differentiation & Cell State(tgid=12) ⓘ

EMT↓, 1,   ERK↓, 1,   ERK∅, 1,   GSK‐3β↓, 1,   Let-7↑, 1,   mTOR↓, 1,   PI3K↓, 1,   PTEN↑, 1,   STAT3↓, 1,   TumCG↓, 9,  

Migration(tgid=13) ⓘ

5LO↓, 1,   CD31↓, 1,   E-cadherin↓, 1,   E-cadherin↑, 1,   Ki-67↓, 1,   miR-200b↑, 1,   MMP2↓, 3,   MMP9↓, 7,   MMPs↓, 1,   N-cadherin↓, 1,   Snail↓, 1,   TumCI↓, 1,   TumCMig↓, 4,   TumCP↓, 5,   TumMeta↓, 2,   Twist↓, 1,   Vim↓, 1,   β-catenin/ZEB1↓, 1,  

Angiogenesis & Vasculature(tgid=14) ⓘ

angioG↓, 5,   angioG↑, 1,   EGFR↓, 1,   Hif1a↓, 3,   VEGF↓, 14,  

Immune & Inflammatory Signaling(tgid=16) ⓘ

COX2↓, 1,   CXCR4↓, 4,   HMGB1↓, 1,   ICAM-1↓, 2,   IKKα↓, 2,   IL6↓, 1,   IL8↓, 1,   Inflam↓, 1,   mPGES-1↓, 1,   NF-kB↓, 5,   p‑NF-kB↓, 1,   p‑NF-kB↑, 1,   p65↓, 1,   p‑p65↓, 1,   PGE2↓, 1,  

Hormonal & Nuclear Receptors(tgid=20) ⓘ

CDK6↓, 1,  

Drug Metabolism & Resistance(tgid=21) ⓘ

ChemoSen↑, 3,   Dose↝, 1,   selectivity↑, 1,  

Clinical Biomarkers(tgid=22) ⓘ

ascitic↓, 1,   EGFR↓, 1,   IL6↓, 1,   Ki-67↓, 1,  

Functional Outcomes(tgid=23) ⓘ

AntiCan↑, 1,   chemoP↑, 1,   chemoPv↑, 1,   TumVol↓, 3,   Weight∅, 1,  
Total Targets: 93

Pathway results for Effect on Normal Cells:


Redox & Oxidative Stress(tgid=1) ⓘ

antiOx↑, 1,   Catalase↑, 1,   GPx↑, 1,   GSTA1↑, 1,   ROS↓, 1,   SOD↑, 1,  

Migration(tgid=13) ⓘ

MMP13↓, 1,  

Immune & Inflammatory Signaling(tgid=16) ⓘ

COX2↓, 2,   IL1β↓, 1,   Inflam↓, 2,   PGE2↓, 1,  

Drug Metabolism & Resistance(tgid=21) ⓘ

BioAv↝, 1,   Half-Life↝, 1,  

Functional Outcomes(tgid=23) ⓘ

cardioP↑, 1,   hepatoP↑, 1,   neuroP↑, 1,   toxicity↓, 1,  
Total Targets: 17

Scientific Paper Hit Count for: VEGF, Vascular endothelial growth factor
2 Beta-Caryophyllene
2 Boswellia (frankincense)
2 Crocetin
2 Thymoquinone
1 Betulinic acid
1 Garcinol
1 Ginger/6-Shogaol/Gingerol
1 Hops (Humulus lupulus)
1 Nimbolide
1 Sulforaphane (mainly Broccoli)
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:6  Cells:%  prod#:%  Target#:334  State#:%  Dir#:1
  wNotes=0  sortOrder:rid,rpid

 

Home Page